Loading viewer...
earnings
Format: PDF earnings
Karyopharm Therapeutics presented first quarter 2022 financial results and business updates on May 5, 2022, featuring commercial highlights for XPOVIO and pipeline updates for selinexor and eltanexor. The presentation covers financial guidance for 2022 net product revenue and R&D/SG&A expenses, along with clinical development progress across multiple myeloma and diffuse large B-cell lymphoma indications.
conference
34 Pages
earnings
40 Pages
IDT
Albemarle Q2 2023 Earnings Presentation | August 3
earningsearnings
27 Pages
Albemarle Corporation
Partner for Growth 2023 Preliminary Results
earningsearnings
55 Pages
Partner for Growth
H World Group Limited Q2 2024 Earnings Call Presentation
earningsearnings
30 Pages
H World Group Limited